This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This collaboration aims to support patients with chronic and complex conditions, particularly in oncology, rheumatology and dermatology. Nearly 3,000 healthcare providers will benefit, as Shields’ broad payer network and access to limited distribution drugs will offer patients more treatment options and cost-saving support.
Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. who intend to evaluate a drug, biologic, medical device, or food for medical purposes that targets a rare disease in a clinical trial. By Sarah Wicks & James E.
Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. billion the drug generated in 2021. billion in 2022. billion, a 26.55
Pfizer also underscored several potential first-in-class or best-in-class programs, such as selective CDK2 and CDK4 inhibitors, as well as data for a BCMA-targeted bispecific antibody for the treatment of multiple myeloma, a HER2-Antibody Drug Conjugate for the treatment of breast cancer and other HER2-expressing cancers. and -50.4%
An IQVIA survey to Neurology, Cardiology, Rheumatology, Dermatology and Ophthalmologists in June 2020 across the lead five European countries showed an average of 30% of patients either “no shows” or still waiting for treatment that was delayed.
COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Topline results will be presented at the American College of Cardiology 70th Annual Scientific Session. Adakveo sales reached USD 37 million. Financials. First quarter.
In pharma marketing, engagement is crucial because it educates HCPs and patients about new treatments, drug safety, and disease management. Short, digestible content formats, such as 60-second expert video snippets, quick-read clinical insights, and infographics summarizing drug efficacy data, improve engagement and retention.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content